Kalaris Therapeutics (NASDAQ:KLRS) Price Target Cut to $25.00 by Analysts at Citizens Jmp

Posted by George Bondi on May 13th, 2026

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) had its price target decreased by Citizens Jmp from $26.00 to $25.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would suggest a potential upside of 428.21% from the company’s previous close.

Other equities analysts have also issued reports about the company. Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a report on Wednesday. Morgan Stanley assumed coverage on shares of Kalaris Therapeutics in a research report on Thursday, April 16th. They set an “overweight” rating and a $14.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.25.

Check Out Our Latest Stock Analysis on KLRS

Kalaris Therapeutics Price Performance

Shares of KLRS stock traded down $0.06 during trading hours on Wednesday, reaching $4.73. The stock had a trading volume of 32,242 shares, compared to its average volume of 75,080. The firm has a market capitalization of $108.81 million, a PE ratio of -1.10 and a beta of 0.15. The firm has a 50-day simple moving average of $6.78 and a 200-day simple moving average of $7.52. Kalaris Therapeutics has a twelve month low of $2.14 and a twelve month high of $11.88.

Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06. On average, equities analysts anticipate that Kalaris Therapeutics will post -2.18 earnings per share for the current year.

Hedge Funds Weigh In On Kalaris Therapeutics

Hedge funds have recently bought and sold shares of the business. RTW Investments LP bought a new position in Kalaris Therapeutics during the fourth quarter valued at about $10,972,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Kalaris Therapeutics during the 4th quarter valued at about $5,908,000. Alyeska Investment Group L.P. bought a new position in shares of Kalaris Therapeutics in the 4th quarter valued at approximately $3,402,000. Ikarian Capital LLC acquired a new stake in Kalaris Therapeutics in the 4th quarter worth approximately $3,038,000. Finally, Woodline Partners LP acquired a new stake in Kalaris Therapeutics in the 3rd quarter worth approximately $1,394,000. 66.05% of the stock is owned by institutional investors and hedge funds.

About Kalaris Therapeutics

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.